Takeda Oncology Pipeline: Investigational Therapies for Cancer Treatment | Takeda Oncology
Our Pipeline
Our Pipeline
We are advancing a pipeline of investigational therapies with the highest potential to reach patients. We are currently focused on four core modalities: antibody drug conjugates (ADCs), bispecifics, small molecules and gamma delta T cell therapies. We are evaluating investigational therapies that leverage these modalities in solid tumors - with a focus on thoracic and gastrointestinal cancers - and hematologic cancers.
These therapies in development are investigational and have not been approved by any regulatory bodies for use in the investigational indications listed below.
| Investigational therapy | Modality | Investigational indication | Phase | ||
Brentuximab vedotin* | |||||
ADC | Newly diagnosed Hodgkin lymphoma (EU) | Phase 3 | |||
Cabozantinib* | |||||
Small molecule | Metastatic castration-resistant prostate cancer (JP) | Phase 3 | |||
Fruquintinib* | |||||
Small molecule | Previously treated metastatic colorectal cancer (JP) | Filed | |||
Dazostinag (TAK-676) | |||||
Small molecule | Solid tumors | Phase 1/2 | |||
Mirvetuximab soravtansine-gynx (TAK-853) | |||||
ADC | Folate receptor alpha (FRα)-positive ovarian cancer (JP) | Phase 1/2 | |||
TAK-012 | |||||
Gamma delta T cell therapy | Acute myeloid leukemia | Phase 1/2a | |||
TAK-186 | |||||
Bispecific | Solid tumors | Phase 1/2 | |||
TAK-280 | |||||
Bispecific | Solid tumors | Phase 1/2 | |||
TAK-500 | |||||
ADC | Solid tumors | Phase 1/2 |
*Marketed products have received approval in one or more jurisdictions.
All programs have global development rights unless otherwise noted.
GL = global (USA, Europe, Japan, China) / EU = Europe / JP = Japan / CN = China / GEM = global emerging markets
Investors
To learn more about Oncology-specific Investor events and information, visit the Takeda Oncology Investor Relations page
